Cholesterol lowering medications
Pro Research Analysisby 
Searched over 200M research papers
Statins as the Foundation of Cholesterol-Lowering Medications
Statins are the most widely used and effective cholesterol-lowering drugs, primarily targeting low-density lipoprotein cholesterol (LDL-C). They work by inhibiting the enzyme HMG-CoA reductase, which is crucial for cholesterol synthesis in the liver. Statins can reduce LDL-C by 20% to 45% and are well tolerated by most patients, making them the cornerstone of therapy for preventing and treating atherosclerotic cardiovascular disease (ASCVD) Ferri2024Xu2020Crîşmaru2020+5 MORE. However, some patients experience side effects or do not reach their LDL-C targets with statins alone Xu2020Bardolia2021.
Ezetimibe and Bile Acid Sequestrants: Additional Oral Options
Ezetimibe is another oral medication that lowers cholesterol by blocking its absorption in the intestines. Used alone, it can reduce LDL-C by about 18%, and when combined with statins, it provides an additional 25% reduction Ferri2024Xu2020Crîşmaru2020+4 MORE. Bile acid sequestrants are also used, either alone or with statins, to further lower LDL-C, especially in patients who cannot tolerate statins Crîşmaru2020Hou2009Pirillo2020.
PCSK9 Inhibitors: Advanced Therapies for High-Risk Patients
PCSK9 inhibitors, such as evolocumab, are injectable drugs that significantly lower LDL-C by 53% to 56% from baseline. They work by preventing the breakdown of LDL receptors in the liver, allowing more cholesterol to be cleared from the blood. These drugs are especially useful for patients who are at high risk for cardiovascular events or who do not achieve their cholesterol goals with oral medications Ferri2024Xu2020Crîşmaru2020+4 MORE. Recent developments include both monoclonal antibodies and small-interfering RNA therapies targeting PCSK9, with ongoing research into oral PCSK9 inhibitors for greater convenience Ferri2024Basak2025.
New and Emerging Cholesterol-Lowering Medications
Bempedoic acid is a newer oral drug that inhibits ATP citrate lyase, another enzyme involved in cholesterol production. It has been shown to reduce major cardiovascular events in both primary and secondary prevention settings Ferri2024Bardolia2021Luo2022. Inclisiran, a small-interfering RNA therapy, is another recent addition that targets PCSK9 and offers promising results for LDL-C reduction Ferri2024Bardolia2021Luo2022.
Combination Therapy for Enhanced Cholesterol Lowering
Combining different classes of cholesterol-lowering medications, such as statins with ezetimibe or PCSK9 inhibitors, can provide greater reductions in LDL-C and help more patients reach their treatment goals. This approach is particularly important for those who are at very high risk or who cannot tolerate high doses of a single medication Xu2020Crîşmaru2020Hou2009+3 MORE.
Trends in Cholesterol-Lowering Medication Use
The use of prescription cholesterol-lowering medications has increased significantly over the past two decades, especially among adults aged 40 and over. Statins remain the most commonly used drugs, but the use of combination therapies and non-statin agents is also rising, particularly among patients with cardiovascular disease, diabetes, or high cholesterol .
Conclusion
Cholesterol-lowering medications play a crucial role in reducing the risk of cardiovascular disease. Statins are the primary therapy, but additional options like ezetimibe, bile acid sequestrants, PCSK9 inhibitors, bempedoic acid, and inclisiran provide effective alternatives and combination strategies for patients who need further LDL-C reduction or cannot tolerate statins. Ongoing research continues to expand the range of available therapies, with a focus on improving efficacy, safety, and patient convenience Ferri2024Xu2020Crîşmaru2020+7 MORE.
Sources and full results
Most relevant research papers on this topic